Notice Number: NOT-CA-17-045

Key Dates
Release Date: March 29, 2017

Issued by
National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) will hold a Pre-Application Technical Assistance Webinar on April 6, 2017 at 12:00 - 1:00 PM EST for RFA-CA-17-023 "Integration and validation of Emerging Technologies to Accelerate Cancer Research (R33)." This funding is to promote research on the advanced development and rigorous validation of new enabling technologies/tools/capabilities with a transformative potential for cancer research and clinical oncology. Specifically, this FOA targets the following four areas designated as scientific priorities:

Area 1: Enhanced experimental and analytical capabilities addressing complexities of cancer development;
Area 2: New capabilities advancing precise clinical diagnosis of cancer patients;
Area 3: Novel predictive ex vivo and/or in silico modeling approaches; and
Area 4: New technologies/approaches to improve biospecimen and data quality.

Applications must be focused on one of these areas and must be based on comprehensive preliminary data substantiating the potential of the proposed technologies/tools/capabilities and the functionality their contributing components. Essential aspect is a rigorous technical validation to ensure that the transformative, enabling potential of the proposed technologies/tools/capabilities for cancer research and/or clinical care is thoroughly verified by the end of the project period.

Webinar speakers will provide pre-application technical assistance and convey important information to prospective grant applicants, including an in-depth discussion of the funding opportunity scope; unique application requirements; unique aspects of application processing; and what to expect in the review process.

To register for the webinar, follow this link.

Participation in this webinar, although encouraged, is optional and is not required for the submission of an application in response to RFA-CA-17-023.

Inquiries

Please direct all inquiries to:

Tony Dickherber, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-547-9980
Email: [email protected]